metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology O2- CHARACTERIZATION OF STEATOTIC LIVER DISEASE AND THE ROLE OF GENETIC BACKGROU...
Journal Information
Vol. 29. Issue S3.
Abstracts of the 2024 Annual Meeting of the ALEH
(December 2024)
Vol. 29. Issue S3.
Abstracts of the 2024 Annual Meeting of the ALEH
(December 2024)
Full text access
O2- CHARACTERIZATION OF STEATOTIC LIVER DISEASE AND THE ROLE OF GENETIC BACKGROUND IN LATIN AMERICA
Visits
240
LUIS ANTONIO DÍAZ PIGA1, Carolina Aguilera2, Gustavo Ayares3, Francisco Idalsoaga3, Mauricio Pizarro3, Fernando Javier Barreyro4, Sebastián Marciano5, Jorge Martínez Morales5, Cristiane Villela-Nogueira6, Nathalie Leite6, Claudia Alves Couto7, Rafael Theodoro7, Mísia Joyner de Sousa Dias Monteiro7, Mario G. Pessoa8, Mario Reis Alvares-da-Silva9, Fátima Higuera de la Tijera10, Adelina Lozano11, Pedro Montes12, Graciela Castro-Narro13, Constanza D. Sabate14..., Manuel Mendizabal14, Francisco Barrera3, Daniel Cabrera15, Mazen Noureddin16, Naim Alkhouri17, Winston Dunn18, Zobair Younossi19, Jeffrey V. Lazarus20, Rohit Loomba1, Claudia Pinto Marques Souza de Oliveira8, Adrian Gadano5, Marco Arrese3, Juan Pablo Arab21Ver más
1 MASLD Research Center, University of California San Diego, San Diego, California, Estados Unidos (EEUU)
2 Departamento de Nutrición y Diabetes, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile
3 Departamento de Gastroenterología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile
4 Departamento de Gastroenterología, Escuela de Medicina, Universidad Nacional de Misiones, Misiones, Argentina
5 Departamento de Gastroenterología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
6 División de Hepatología, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brasil
7 Departamento de Gastroenterologia, Universidade Federal de Minas Gerais, Belo Horizonte, Brasil
8 Departamento de Gastroenterologia, Universidade de São Paulo, Sao Paulo, Brasil
9 Departamento de Gastroenterologia, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brasil
10 Departamento de Gastroenterología, Hospital General de México "Dr. Eduardo Liceaga", Mexico City, México
11 Departamento de Gastroenterología, Clínica Avendaño, Miraflores, Perú
12 Departamento de Gastroenterología, Hospital Nacional – Daniel Alcides Carrión, Bellavista, Perú
13 Department of Gastroenterology, Instituto Nacional de Ciencias Médicas y Nutrición “Salvador Zubirán”, Mexico City, México
14 Departamento de Gastroenterología, Hospital Universitario Austral, Buenos Aires, Argentina
15 Centro de Investigación e Innovación en Biomedicina, Universidad de los Andes, Santiago, Chile
16 Houston Methodist Hospital, Houston, Texas, Estados Unidos (EEUU)
17 Department of Hepatology, Arizona Liver Health, Chandler, Arizona, Estados Unidos (EEUU)
18 University of Kansas Medical Center, Kansas, Estados Unidos (EEUU)
19 Center for Liver Diseases and Beatty Liver and Obesity Research Program at Inova Health System, Falls Church, Virginia, Estados Unidos (EEUU)
20 CUNY Graduate School of Public Health and Health Policy (CUNY SPH), New York, New York, Estados Unidos (EEUU)
21 Division of Gastroenterology, Hepatology, and Nutrition, Department of Internal Medicine, Virginia Commonwealth University School of Medicine, Richmond, Virginia, Estados Unidos (EEUU)
Ver más
This item has received
Article information
Abstract
Full Text
Download PDF
Statistics
Figures (1)
Special issue
This article is part of special issue:
Vol. 29. Issue S3

Abstracts of the 2024 Annual Meeting of the ALEH

More info
Conflict of interest

Yes, FONDECYT #1241450

Introduction and Objectives

Although Latinos living in the United States are at higher risk of steatotic liver disease (SLD), information from Latin American countries is extremely scarce. We aimed to characterize SLD in Latin America and explore the role of the common genetic variants in this region.

Patients / Materials and Methods

Cross-sectional multicenter study including individuals with SLD who undergo liver biopsy or transient elastography (TE) between 2003–2024. TE thresholds were established as follows: significant fibrosis (F2) ≥8.2 kPa, advanced fibrosis (F3) ≥9.7 kPa, and cirrhosis (F4) ≥13.6 kPa. Analyses included logistic binary regression.

Results and Discussion

We included 2,159 patients (93.7% metabolic dysfunction-associated SLD and 6.3% alcohol-associated liver disease) from 13 centers in 5 countries (Argentina, Brazil, Chile, Mexico, and Peru). Mean age was 54.3±14.3 years old, 58.8% were female, and 60.2% had a liver biopsy. Around 18% had significant fibrosis, 18.7% advanced fibrosis, and 16.2% had cirrhosis. Additionally, 21.8% were homozygous carriers of the rs738409 risk polymorphism (PNPLA3 I148M variant), 42.5% were heterozygotes, and 35.7% were non-carriers. In an adjusted multivariable model, only age (odds ratio [OR]:1.03; 95%CI:1.01–1.04; p=0.030), body mass index (BMI) (OR:1.04; 95%CI:1.01–1.08, p=0.008), prediabetes/diabetes (OR:2.41; 95%CI:1.48–3.91, p<0.0001), and PNPLA3 risk allele carriers (heterozygotes: OR:2.86, 95%CI:1.78–4.61; p<0.0001, and homozygous: OR:25.37, 95%CI:4.30–149.54; p<0.001) were associated with a higher risk of advanced fibrosis. Similar results were observed in multivariable models to assess the risk of cirrhosis. Prevalence of advanced fibrosis or cirrhosis was higher in those with prediabetes/diabetes and homozygous carriers of the PNPLA3 I148M variant than those without both risk factors (48.6% vs. 27.9%, p<0.0001) (Figure).

Conclusions

Age, BMI, prediabetes, diabetes, and carriers of the PNPLA3 risk allele carriers were the leading risk factors for advanced fibrosis in SLD. PNPLA3 I148M variant carriers are frequent in SLD patients in Latin America, and genotyping could be established to stratify the risk of liver fibrosis routinely in clinical practice. (Supported Fondecyt #1241450)

Full text is only available in PDF
Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos